Compound Libraries

- A unique collection of 3150 anticancer drugs for high throughput screening (HTS) and high content screening (HCS); - Bioactivity and safety profiled in (confirmed by) pre-clinical and clinical settings (research and trials), an effective tool for molecular mechanism of tumorigenesis, and anti-tumor drug repositioning drug discovery; - Covers various major targets including PI3K, HDAC, mTOR, CDK, Aurora Kinase, JAK, etc; involved in 15 different cancer research areas, such as lung cancer, breast cancer, leukemia, lymphoma, etc. - Detailed compound information with structure, target, activity, IC50 value, and biological activity description; - Structurally diverse, medicinally active, and cell permeable; - NMR and HPLC validated to ensure high purity and quality;

- 48Chemotherapeutic drugs that can be used for high-throughput and high-content screening. - Includes common chemotherapy drugs such as paclitaxel, cyclophosphamide, cytarabine, doxorubicin, etc. - Detailed instructions, compound structures, target information, IC50 values, activity descriptions, etc. - Various detection techniques such as NMR, HPLC/LCMS to ensure correct structure, high purity and reduce the false-positive rates.

- 119 tumor-targeted drugs that can be used for high-throughput and high-content screening. - Targets include EGFR, VEGFR, c-Met, Bcr-Abl, HER2, etc. - All compounds have known and good biological activity, safety and bioavailability. - Detailed instructions, compound structures, target information, IC50 values, activity descriptions, etc. - Various detection techniques such as NMR, HPLC/LCMS to ensure correct structure, high purity and reduce the false-positive rates.

- A unique collection of 3580 compounds with known anti-cancer activity for high throughput screening (HTS) and high content screening (HCS); - Effective tool for molecular mechanism of tumorigenesis, and anti-tumor drug screening; - Covers various major targets including PI3K, HDAC, mTOR, CDK, Aurora Kinase, JAK, etc. - Detailed compound information with structure, target, activity, IC50 value, and biological activity description; - Structurally diverse, medicinally active, and cell permeable; - NMR and HPLC validated to ensure high purity and quality;

- A unique collection of 523 compounds acting on immune-oncology therapeutic targets can be used for high throughput and high content screening； - Targets include PD-1/PD-L1, HER2, STAT3, CTLA4, IDO, STING, CCR, CXCR, TLR, etc. - Detailed compound information with structure, target, and biological activity description； - NMR and HPLC validated to ensure high purity and quality.

- Quantity: well-chosen 1468 anti-tumor compounds with unique structures; - High antitumor activity: 99% of compounds with IC50 below 3 μM; - Covers 42 tumor related targets with each compound having clear target; - Detailed information: each compound has information about activity testing method, providing reference for your experimental design; - HNMR/LCMS validated to ensure high purity and quality; - A supplemental tool for anticancer drug development and target identification.

- A unique collection of 2103 compounds with anti-lung cancer therapeutic activity or targeting lung cancer’s major signaling pathways, can be used for anti-lung cancer drug discovery and mechanism study； - Targets include EGFR, PI3K, FGFR, HER2, ALK, c-Met, etc.； - Some compounds have been in market or in clinical trials; - Detailed compound information with structure, target, and biological activity description； - NMR and HPLC validated to ensure high purity and quality.

- A unique collection of 2440 compounds with anti-breast cancer therapeutic activity or targeting breast cancer’s major signaling pathways, can be used for anti-breast cancer drug discovery and mechanism study； - Targets include HER-2, VEGF, EGFR, PARP, CDK4/6, HSP, PD-1, SET7/9, BRCA, etc.； - Some compounds have been in market or in clinical trials; - Detailed compound information with structure, target, and biological activity description； - NMR and HPLC validated to ensure high purity and quality.

- A unique collection of 2508 pancreatic cancer related compounds can be used in HTS and HCS; - Some of them have been approved for clinical use or in clinical trial phases; - Detailed compound information with structure, target, IC50, and biological activity description; - NMR and HPLC/LCMS validated to ensure high purity and quality.